Nkarta (NKTX) Competitors

$2.68 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.67 -0.01 (-0.52%)

As of 06:01 PM Eastern

NKTX vs. DRUG, AMPH, SPRY, RLMD, and EIKN

Should you buy Nkarta stock or one of its competitors? MarketBeat compares Nkarta with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nkarta include Bright Minds Biosciences (DRUG), Amphastar Pharmaceuticals (AMPH), ARS Pharmaceuticals (SPRY), Relmada Therapeutics (RLMD), and EIKN (EIKN). These companies are all part of the "pharmaceutical products" industry.

How does Nkarta compare to Bright Minds Biosciences?

Nkarta (NASDAQ:NKTX) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Nkarta presently has a consensus target price of $10.75, suggesting a potential upside of 301.12%. Bright Minds Biosciences has a consensus target price of $128.60, suggesting a potential upside of 72.52%. Given Nkarta's higher possible upside, analysts plainly believe Nkarta is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 8.4% of Nkarta shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nkarta has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.35, meaning that its share price is 635% less volatile than the broader market.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$1.93	N/A

Bright Minds Biosciences' return on equity of -28.62% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Bright Minds Biosciences	N/A	-28.62%	-28.08%

In the previous week, Nkarta had 8 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 10 mentions for Nkarta and 2 mentions for Bright Minds Biosciences. Nkarta's average media sentiment score of 0.83 beat Bright Minds Biosciences' score of 0.00 indicating that Nkarta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Nkarta beats Bright Minds Biosciences on 9 of the 14 factors compared between the two stocks.

How does Nkarta compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, Nkarta had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 10 mentions for Nkarta and 9 mentions for Amphastar Pharmaceuticals. Nkarta's average media sentiment score of 0.83 beat Amphastar Pharmaceuticals' score of 0.05 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nkarta	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.09	$98.09M	$1.66	10.73
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Amphastar Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 8.4% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Nkarta's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Nkarta	N/A	-30.90%	-24.20%

Amphastar Pharmaceuticals currently has a consensus price target of $24.50, suggesting a potential upside of 37.49%. Nkarta has a consensus price target of $10.75, suggesting a potential upside of 301.12%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Amphastar Pharmaceuticals beats Nkarta on 9 of the 16 factors compared between the two stocks.

How does Nkarta compare to ARS Pharmaceuticals?

Nkarta (NASDAQ:NKTX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Nkarta presently has a consensus price target of $10.75, indicating a potential upside of 301.12%. ARS Pharmaceuticals has a consensus price target of $28.25, indicating a potential upside of 294.00%. Given Nkarta's stronger consensus rating and higher possible upside, equities analysts plainly believe Nkarta is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Nkarta has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Nkarta has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Nkarta's return on equity of -30.90% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
ARS Pharmaceuticals	-200.00%	-130.75%	-58.58%

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 8.4% of Nkarta shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, ARS Pharmaceuticals had 1 more articles in the media than Nkarta. MarketBeat recorded 11 mentions for ARS Pharmaceuticals and 10 mentions for Nkarta. Nkarta's average media sentiment score of 0.83 beat ARS Pharmaceuticals' score of 0.00 indicating that Nkarta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nkarta has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
ARS Pharmaceuticals	$98.99M	7.19	-$171.30M	-$2.01	N/A

Summary

Nkarta beats ARS Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Nkarta compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Relmada Therapeutics has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Relmada Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 70.70%. Nkarta has a consensus price target of $10.75, suggesting a potential upside of 301.12%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Nkarta's return on equity of -30.90% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Nkarta	N/A	-30.90%	-24.20%

In the previous week, Nkarta had 5 more articles in the media than Relmada Therapeutics. MarketBeat recorded 10 mentions for Nkarta and 5 mentions for Relmada Therapeutics. Nkarta's average media sentiment score of 0.83 beat Relmada Therapeutics' score of -0.16 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nkarta	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 8.4% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Nkarta beats Relmada Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Nkarta compare to EIKN?

EIKN (NASDAQ:EIKN) and Nkarta (NASDAQ:NKTX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

80.5% of Nkarta shares are held by institutional investors. 8.4% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EIKN	N/A	N/A	N/A	N/A	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

EIKN's return on equity of 0.00% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EIKN	N/A	N/A	N/A
Nkarta	N/A	-30.90%	-24.20%

In the previous week, Nkarta had 8 more articles in the media than EIKN. MarketBeat recorded 10 mentions for Nkarta and 2 mentions for EIKN. Nkarta's average media sentiment score of 0.83 beat EIKN's score of 0.11 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
EIKN	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nkarta	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

EIKN currently has a consensus price target of $25.20, suggesting a potential upside of 136.84%. Nkarta has a consensus price target of $10.75, suggesting a potential upside of 301.12%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than EIKN.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EIKN	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Nkarta	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Nkarta beats EIKN on 7 of the 10 factors compared between the two stocks.

Get Nkarta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTX vs. The Competition

Export

Metric	Nkarta	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$191.73M	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-2.00	18.70	20.58	25.11
Price / Sales	N/A	278.20	577.42	91.32
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	0.61	6.57	9.68	6.60
Net Income	-$104.08M	$24.30M	$3.55B	$335.71M
7 Day Performance	-18.29%	-3.56%	-2.07%	-2.03%
1 Month Performance	-22.77%	-7.86%	-3.90%	-1.90%
1 Year Performance	57.65%	51.80%	29.39%	27.36%

Nkarta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTX Nkarta	3.9158 of 5 stars	$2.68 flat	$10.75 +301.1%	+54.0%	$191.73M	N/A	N/A	140	Earnings Report Analyst Upgrade Gap Down
DRUG Bright Minds Biosciences	1.9387 of 5 stars	$75.00 -3.2%	$128.60 +71.5%	+127.3%	$753.95M	N/A	N/A	N/A	Earnings Report
AMPH Amphastar Pharmaceuticals	4.1484 of 5 stars	$17.20 +2.0%	$24.50 +42.4%	-30.8%	$743.85M	$719.89M	10.36	1,976
SPRY ARS Pharmaceuticals	2.8176 of 5 stars	$7.30 -1.7%	$28.25 +287.0%	-46.3%	$737.31M	$98.99M	N/A	90	Earnings Report Analyst Upgrade
RLMD Relmada Therapeutics	2.6016 of 5 stars	$6.34 -8.1%	$12.00 +89.3%	+1,275.3%	$723.74M	N/A	N/A	10	Earnings Report High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTX) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nkarta (NKTX) Competitors

NKTX vs. DRUG, AMPH, SPRY, RLMD, and EIKN

How does Nkarta compare to Bright Minds Biosciences?

Summary

How does Nkarta compare to Amphastar Pharmaceuticals?

Summary

How does Nkarta compare to ARS Pharmaceuticals?

Summary

How does Nkarta compare to Relmada Therapeutics?

Summary

How does Nkarta compare to EIKN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nkarta (NKTX) Competitors

NKTX vs. DRUG, AMPH, SPRY, RLMD, and EIKN

How does Nkarta compare to Bright Minds Biosciences?

Do analysts rate NKTX or DRUG?

Do insiders and institutionals have more ownership in NKTX or DRUG?

Which has more risk and volatility, NKTX or DRUG?

Which has better earnings & valuation, NKTX or DRUG?

Is NKTX or DRUG more profitable?

Does the media prefer NKTX or DRUG?

Summary

How does Nkarta compare to Amphastar Pharmaceuticals?

Does the media favor AMPH or NKTX?

Which has preferable earnings & valuation, AMPH or NKTX?

Which has more volatility & risk, AMPH or NKTX?

Do institutionals & insiders have more ownership in AMPH or NKTX?

Is AMPH or NKTX more profitable?

Do analysts prefer AMPH or NKTX?

Summary

How does Nkarta compare to ARS Pharmaceuticals?

Do analysts recommend NKTX or SPRY?

Which has more risk & volatility, NKTX or SPRY?

Is NKTX or SPRY more profitable?

Do insiders & institutionals believe in NKTX or SPRY?

Does the media prefer NKTX or SPRY?

Which has preferable earnings & valuation, NKTX or SPRY?

Summary

How does Nkarta compare to Relmada Therapeutics?

Which has better earnings and valuation, RLMD or NKTX?

Which has more risk & volatility, RLMD or NKTX?

Do analysts prefer RLMD or NKTX?

Is RLMD or NKTX more profitable?

Does the media favor RLMD or NKTX?

Do insiders and institutionals have more ownership in RLMD or NKTX?

Summary

How does Nkarta compare to EIKN?

Do institutionals and insiders have more ownership in EIKN or NKTX?

Which has preferable earnings and valuation, EIKN or NKTX?

Is EIKN or NKTX more profitable?

Does the media favor EIKN or NKTX?

Do analysts recommend EIKN or NKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools